Table 1. Trend of macrolide-resistant Mycoplasma pneumoniae prevalence and dominant sequence types in Korea

Ann Clin Microbiol 2025;29(3):10. Macrolide-resistant Mycoplasma pneumoniae: laboratory diagnosis and epidemiology

Table 1. Trend of macrolide-resistant Mycoplasma pneumoniae prevalence and dominant sequence types in Korea

Period	Sample (n)	MRMP prevalence (%)	Dominant ST / clone	Notes	Reference
2000–2011 (longitudinal)	2,089 specimens / 255 MP⁺ / 80 with mutation	2.9 (2003) → 62.9 (2011)	Not typed	National longitudinal trend	[10]
2010 (Oct–Nov)	195 / 17 MP⁺	17.6 (3/17, A2063G)	Not typed	MP positive in primary clinic (12.1%) vs. tertiary hospital (2.8%)	[27]
2015	94 patients	87.2 (82/94)	Not typed	Pediatric; A2063G dominant	[33]
2018–2020	1,063 enrolled / 454 MP⁺	78.4 (all A2063G)	Not typed	Prospective multicenter	[34]
2019–2020	1,228 specimens / 93 MP⁺	Overall 78.5 (73/93); ST3 98.5%; ST14 38.9%	ST3 71.0% / ST14 19.4% (3 novel STs)	4 hospitals; ST3 → ST14 transition	[45]
2023 (Sep–Dec)	474 screened / 374 confirmed	87.0	Not typed	13 major hospitals; corticosteroid co-prescription 55.6%	[28]

Not typed indicates that sequence typing was not performed in the original study. Abbreviations: MP, Mycoplasma pneumoniae; MRMP, macrolide-resistant Mycoplasma pneumoniae; ST, sequence type.